Drug, bio-affecting and body treating compositions inventions 06/06

20060142179 - 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders: where R1 and R2 are each independently H or a C1-C4 hydrocarbon; R3 is H, and R4 is a moiety capable of crossing the blood brain barrier selected from the group consisting of: an amino acid, a peptide, transferrin, gluconate, lactate, citrate, malate, fumarate, benzoate, salicylate, pyruvate and propionate. The...

20060142180 - Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors: Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as...

20060142178 - Method of treating cancer: The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the...

20060142181 - Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes: M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin,...

20060142182 - Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders: where R1 is H, C1-C4 alkyl and OH; R2 in is H, C1-C4 alkyl and OH; R3 is H and C1-C4 alkyl; R4 is H and C1-C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2-C6 alkyl; and R6...

20060142183 - Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections: The present invention related to a new composition, use and method to improve the cure of infections caused by antibiotic resistant microbial pathogens, in particular beta-lactam resistant microorganisms. Lactoferrin (LF) or Lactoferricin (LFC) can be administrated alone or in combination with antibiotic to affect growth, physiology and morphology of targeted...

20060142184 - Protein based oral lubricant: The present invention relates to formulations containing phosphoprotein, designed for use as oral lubricant or as artificial saliva, methods of using the formulations and processes for the preparation of the formulations....

20060142186 - Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer's disease: Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease include administration of gonadotropin-releasing hormone analogues in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists....

20060142187 - Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity: The present invention is based, at least in part, on the discovery that plasma C1INH contains a sialyl Lewisx related moiety on its N-glycan and is capable of binding selectin molecules. The invention provides methods for modulating cell-to-cell adhesion or cell migration comprising contacting a cell with a C1INH-type protein...

20060142185 - Use of lupin conglutin for the treatment of type ii diabetes: A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of...

20060142199 - Cd-44 like protein: The present invention concerns a novel CD44-like protein receptor. In particular, isolated nucleic acid molecules are provided encoding the CD44-like protein. CD44-like polypeptides are also provided, as are screening methods for identifying agonists and antagonists capable of enhancing or inhibiting CD44-like protein-mediated signaling. The invention further concerns therapeutic methods for...

20060142198 - Compositions for treating wounds and processes for their preparation: The present invention provides a process for obtaining growth factors by treating a growth factor starting material to release growth factors from the growth factor starting material and recovering growth factors from the treated growth factor starting material. The growth factor obtained can be used in compositions to treat humans....

20060142200 - Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia: This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administrating to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum...

20060142189 - Methods and agents for treating axonal damage, inhibition of neurotransmitter release and pain transmission, and blocking calcium influx in neurons: The present invention pertains to methods to promote outgrowth of, or extension across a substrate of, neuronal cells by inhibiting the interaction between the cytoplasmic tail of the L1-CAM cell surface adhesion molecule and the cytoskeletal protein ankyrin. The invention also pertains to a method to treat diseases characterized by...

20060142194 - Methods and compounds for treating brain amyloidosis: The present invention discloses the use of (i) a fragment of the amyloid precursor protein (APP); or, (ii) a derivative of (i); or, (iii) a functional mimetic of (i) or (ii), in the preparation of a medicament for modulating CNS levels and/or activity of a member of the neprilysin family....

20060142188 - Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof: Monkey alpha-7 neuronal nicotinic acetylcholine receptor polypeptides, as well as the DNA (RNA) encoding such polypeptides, are disclosed. Also disclosed are methods for utilizing such polypeptides in diagnostic assays for identifying mutations in nucleic acid sequences encoding the polypeptides of the present invention, for detecting altered levels of the polypeptide...

20060142195 - Non-neurotoxic plasminogen activating factors for treating of stroke: The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans....

20060142193 - Selective inhibition of rock1 in cardiac therapy: The present invention is directed to the treatment and/or prevention of disease as it relates to Rho kinase. In specific embodiments, disease is treated and/or prevented through the administration of an agent that selectively inhibits ROCK1. In specific embodiments, it inhibits ROCK1 and not ROCK2. In other specific embodiments, the...

20060142192 - Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes...

20060142190 - Synthetic peptide, inhibitor to dna viruses: The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which contains the active domain and which we...

20060142197 - Tnf receptor and steroid hormone in a combined therapy: The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous separate or sequential...

20060142196 - Uses of gdnf and gdnf receptor: GDNFRα, GDNFRα extracellular domain (ECD), GDNFRα variants, chimeric GDNFRα (e.g., GDNFRα immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFRα-ligands, for example GDNF, by providing GDNFRα to...

20060142191 - Viral complement control proteins for eye disorders: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein...

20060142201 - Novel x-conotoxin peptides (-1): An isolated, synthetic or recombinant χ-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is...

20060142202 - Compositions and methods for targeted delivery of immune response modifiers: The present invention provides immunomodulatory compositions include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the...

20060142203 - Compositions and methods comprising protein activated receptor antagonists: Compositions and methods comprising protein activated receptor antagonists are provided More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to protein activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions...

20060142205 - Compositions capable of reducing elevated blood urea concentration: The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse...

20060142204 - Pyrrolidine derivatives for use in treating heaptitis c virus infection: The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with...

20060142207 - Compositions and methods for treating cancer: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells....

20060142208 - Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic...

20060142209 - Glucopyranosyloxypyrazole derivatives and medicinal use thereof: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a...

20060142206 - Novel difluorinated gem compounds, preparation methods thereof and applications of same: This invention relates to a mini-type electric vehicle, which is mainly used for individual person or traffic in a certain field. It includes frame, seat, front & rear wheel, driving device, battery, steering system and front wheel suspension device. A casing, where the battery is placed on, protrudes forward at...

20060142210 - Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture: Glucopyranosyl-substituted benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders....

20060142211 - Chromones and chromone derivatives and uses thereof: The present invention relates to chromones, novel chromone derivatives, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and treatment of septic shock, organ injury and other disorders. The compounds described herein can...

20060142213 - Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein: The present invention provides methods for treating neuropathological states and neurogenic inflammatory states in a subject. The present invention also provides methods for identifying compounds that can be used to treat such states. Preferably, the compounds alter the distribution of NMDA glutamate receptor NR1 subunit in cells, and/or alter the...

20060142212 - Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer: A nutrient pharmaceutical formulation composition useful for treating cancer comprising ascorbic acid, L-lysine, L-proline and at least one polyphenol compound selected from the group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, catechin and the use of the composition in treating cancer and other tumors are provided. A nutrient pharmaceutical...

20060142214 - 3,6-bicyclolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060142216 - Parasiticidal composition: An anti-parasiticidal composition presented as a topical “pour-on” product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by...

20060142215 - Tetracyclic bicyclolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20060142217 - Carbohydrate based anti-bacterials: A method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula I,...

20060142227 - Amphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier: The invention provides molecules comprising a nucleic acid, a hydrophobic moiety and a positively charge moiety, useful in the delivery of a nucleic acid sequence across a cellular membrane. The invention further relates to the use of these molecules for the delivery of a nucleic acid sequence to the brain...

20060142236 - Antisense oligonucleotide modulation of raf gene expression: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided....

20060142231 - Dna damage repair inhibitors for treatment of cancer: DNA Damage Repair Inhibitors for Treatment of Cancer The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in...

20060142230 - Double-stranded ribonucleic acid molecules having ribothymidine: The invention relates to a double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5′-methyl-pyrimidine, and a method of using such modified dsRNA molecule to increase stability of RNA when in contact with a...

20060142233 - Gene expression and genetic changes implicated in alcoholism: Polynucleotides, polypeptides, kits and methods are provided related to regulated genes characteristic of alcoholism....

20060142234 - Injectable non-aqueous suspension: The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions....

20060142218 - Method of controlling telomere length: A method of controlling telomere length wherein the method comprises introducing into a cell a DNA encoding Mre11 protein or a DNA encoding a protein comprising Mre11 protein wherein a part of the nuclease domain, the C-terminal domain or the whole thereof is modified or deleted....

20060142235 - Method of reducing and treating uvb-induced immunosuppression: Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs....

20060142228 - Methods and compositions concerning sirna's as mediators of rna interference: The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,...

20060142223 - Methods for xenotopic expression of nucleus-encoded plant and protist peptides and uses thereof: The present invention provides a method for introducing a functional peptide encoded by a plant or protist nucleic acid sequence into a mitochondrion of a mammalian cell, and a pharmaceutical composition comprising the nucleic acid sequence. The present invention also provides a method for correcting a phenotypic deficiency in a...

20060142229 - Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof: The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double...

20060142224 - Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds....

20060142222 - Novel gene relating to fibrotic conditions: This discloses a novel human or rat polypeptide useful in improving and/or preventing organ fibrosis and a polynucleotide encoding the aforementioned polypeptide, an expression vector containing the aforementioned polynucleotide, and a cell transfected with the aforementioned expression vector. The aforementioned polynucleotide shows a remarkable decrease in the expression dose in...

20060142232 - Oligomeric compositions and methods: The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life....

20060142219 - Pharmaceutical compositions comprising an hiv envelope protein and cd4: Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein....

20060142220 - Protein modification: The present invention relates to a method for changing the half-life of a glycosylated compound by the modification of its O-linked carbohydrates. This modification is preferably carried out enzymatically and aimed at extending the half-life of the compound. Both in vivo and in vitro modification protocols may be used....

20060142226 - Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene...

20060142225 - Rna interference mediated inhibition of cyclin dependent kinase-2 (cdk2) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CDK2 gene expression...

20060142221 - Vaccine: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions...

20060142237 - Method for treatment of multiple sclerosis: Use of an A3 adenosine receptor agonist in the preparation of a pharmaceutical composition for the treatment of an individual suffering from multiple sclerosis. The composition is preferably orally administered. Also disclosed is a pharmaceutical composition for the treatment of multiple sclerosis that comprises an effective amount of an A3...

20060142238 - Chemical compounds: Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety....

20060142240 - Mutagenic nucleoside analogs for the treatment of viral disease: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs....

20060142239 - Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine: A method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, such as colorectal cancer, which comprises one of: the administration of...

20060142241 - Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis: The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having a therapeutic effect in subjects with...

20060142242 - Starch derivatives and other derivatives, production processes therefor, and wound healing applications therefor: Novel phosphate starch derivatives are useful in wound healing. Novel phosphorylated cottons are useful in wound healing. Silver-derivatized wound care products are provided which survive washing and remain part of the wound care product. Silver-derivatized wound care products are provided that have favorable elastase-sequestering activity while advantageously appearing white-colored, without...

20060142244 - Geranyl compounds: v

20060142243 - Use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treatment of urogenital tract infection. N-acetyl-D-glucosamine exhibits a function of suppressing the transplantation of exotic microorganisms and promoting the repair of topical skin tissue, and the formulation comprising it as a main active component is...

20060142246 - 2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin d3 and its uses: This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis...

20060142245 - Inhibitors of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule....

20060142247 - Tricyclic heterocycles: e

20060142248 - Xanthurenic acid derivative pharmaceutical compositions and methods related thereto: R4 and R8 are independently H, (═O); hydroxy; or optionally substituted saccharide, aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or —P(O)(ORa)(ORb) or —NRaRb, where Ra and Rb are independently H, or optionally substituted aliphatic, cycloalkyl or heterocycloalkyl, aryl or heteroaryl; or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically...

20060142249 - Ophthalmic use: The present invention relates to the use of a GABA-C-antagonist in the preparation of a medicament for the treatment of myopia....

20060142250 - Protein tyrosine phosphatase inhibitors and methods of use thereof: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions...

20060142251 - Anti-microbial agents derived from methionine sulfoximine analogues: Novel antimicrobial compositions containing analogues of L-methionine-SR-sulfoximine (MSO) that are effective in treating intracellular pathogen infections are provided. Specifically, the compositions provided are MSO analogues having superior antimicrobial activity with significantly less toxicity as compared to MSO. These MSO analogues are suitable for use in treating infection in animals including...

20060142252 - Tubulin binding agents and corresponding prodrug constructs: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare...

20060142253 - Methods for treating neoplastic, angiogenic, vascular, fibroblastic, and/or immunosuppressive irregularities of the eye and/or joint via administration of combretastatin based medicaments, and iontophoretic devices for delivering combretastatin based medi: A method for treating neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularities of the eye and/or joint of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular and/or joint area having a neoplastic, angiogenic, fibroblastic, immunosuppressive, infectious, metabolic,...

20060142254 - Antipyretic preparation containing xylitol: The invention relates to an antipyretic preparation intended to be administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol. The invention also relates to the...

20060142255 - Hypocholesteremic preparations containing phytostenolesters of conjugated fatty acids, and methods of reducing serum cholesterol levels using the same: A hypocholesteremic preparation containing at least one phytostenol ester of a conjugated fatty acid having from about 6 to about 24 carbon atoms is disclosed. Methods of reducing serum cholesterol content in a mammal via administration of hypocholesteremic preparations described herein are also disclosed....

20060142256 - Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometricosis: The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination....

20060142257 - Male contraceptive formulation comprising norethisterone: A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as...

20060142258 - Estrogen replacement therapy: This invention relates to methods and pharmaceutical compositions for providing estrogen replacement therapy in penmenopausal, menopausal, and postmenopausal women through the continuous administration of conjugated estrogens....

20060142259 - Compounds, pharmaceutical compositions and methods for inhibiting hiv infectivity: Compounds that possess anti-infective activity are described. Methods of using these compounds for the treatment or prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS) are also described. The compounds inhibit HIV infectivity and do not exhibit significant cytotoxicity in HIV producing cells....

20060142260 - Water-soluble anionic bacteriochlorophyll derivatives and their uses: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2...

20060142261 - Crystalline anhydrous cefdinir and crystalline cefdinir hydrates: A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed....

20060142262 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto: n

20060142264 - Novel amide derivatives: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which...

20060142265 - Compositions comprising multiple bioactive agents, and methods of using the same: In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent....

20060142263 - New substituted pyrrolidinones, their manufacture and their use as medicaments:

20060142266 - Compounds and their uses: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP....

20060142268 - 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or salt thereof: To provide a compound having a superior arginine vasopressin antagonism. A novel 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or a pharmaceutically acceptable salt thereof....

20060142267 - Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods: The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), —OSO2(C2-C6 alkyl) or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino,...

20060142269 - New compounds: e

20060142270 - Preventing or treating agent for glaucoma: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension,...

20060142271 - Novel lapacho compounds and methods of use thereof: The invention provides new synthetic lapacho derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of psoriasis or cancer or precancerous conditions....

20060142272 - Pyrrolo [2, 1-c] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents: e

20060142275 - Prenyl transferase inhibitors:

20060142274 - Use of selected cgrp antagonists for combating menopausal hot flushes: The invention relates to the use of selected CGRP antagonists, the physiologically acceptable salts thereof or the hydrates of the hydrates of the salts thereof for combating menopausal hot flushes....

20060142273 - Use of selected cgrp-antagonists in combination with other antimigraine drugs for the treatment of migraine: The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or...

20060142276 - Therapeutic agent for senile dementia: e

20060142278 - Mitotic kinesin inhibitors: The present invention relates to bicyclic dihydrepyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals....

20060142277 - Substituted aralkyl derivatives: The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation....

20060142279 - Treatment of latent tuberculosis: a pharmaceutically acceptable salt, a quaternary amine, a N-oxide, a tautomeric form or a stereochemically isomeric form thereof wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy,...

20060142280 - Cyclothiocarbamate derivatives as progesterone receptor modulators: p

20060142281 - Indolinone derivatives:

20060142282 - Combination effective for the treatment of impotence: This invention relates to the treatment of erectile dysfunction with a combination of (1) a compound selected from α-adrenergic receptor antagonists, and (2) a compound selected from agents which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compositions...

20060142283 - Crystalline form iv of linezolid: The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering...

20060142284 - Novel compounds: The present invention relates to anilinopyrazole derivatives, methods for the preparation of such anilinopyrazoles, and use of such anilinopyrazoles in the treatment of certain diseases or conditions. In particular, the present invention relates to a nilinopyrazole derivatives useful as CDK2 inhibitors and use of the anilinopyrazoles in the treatment of...

20060142285 - Pharmaceutical composition comprising n-aryl n' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome: e

20060142286 - Cyclic hydroxylamine as psychoactive compounds: A compound of formula (I): in which X represents O or CH2; R3 and R4 each independently represent hydrogen or C1-6 alkyl; p represent 0 or 1; and R represents a five- or six-membered saturated or unsaturated ring selected from: formula (II), (III) and (IV); or R represents a five-...

20060142288 - Combinations and methods for headaches: The present invention provides pharmaceutical agents for preventing headaches, especially headaches associated with migraine, tension headaches, and chronic daily headaches. The prophylactic treatments in accordance with the present invention can reduce the frequency of headaches, such as migraine attacks, as well as reducing their severity and duration when they do...

20060142290 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are...

20060142289 - Method of treating migraine headaches: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about...

20060142287 - Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer: An improved adjuvant treatment of stage I or II breast cancer in which patients are administered a chemotherapeutic agent active in breast cancer is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of...

20060142291 - Use of formaldehyde and formaldehyde-releasing compounds in a composition for controlling mycobacteria: The invention relates to the use of a bactericide selected from formaldehyde and formaldehyde-releasing compounds in a composition for controlling mycobacteria, for example in a cooling lubricant....

20060142292 - Water-soluble phenylpyridazine derivative and medicine containing the same: Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-β production, high water solubility...

20060142293 - Phthalazinone derivatives: e

20060142294 - Novel compounds for treatment of cancer and disorders associated with angiogenesis function: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian...

20060142295 - Method of treating cancer with quinolone carboxylic acid derivatives: This invention relates to a method of treating a hyper-proliferative disorder comprising the administration of an effective amount of a compound of Formula (I) to a patient in need thereof....

20060142296 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders: Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060142297 - Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine: The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent gemcitabine, a pharmaceutical composition comprising such a combination and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer....

20060142298 - Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with new aminium salts of 1,2,3-triazoles which can be used as prodrugs to improve the solubility or pharmaceutical properties of 1,2,3-triazole containing compounds. More particularly, the present disclosure...

20060142299 - Crystalline aripiprazole solvates: Alcoholates of aripiprazole are useful as pharmaceuticals and/or as intermediates in making aripiprazole Form A or Form B....

20060142300 - Anhydrous crystalline forms of i and ii of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1- piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin): The present invention relates to the novel anhydrous crystalline forms I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) which can be depicted as Formula (I). The present invention also relates to methods of making the anhydrous Forms I and II of Gatifloxacin, use of the forms and methods for preparing...

20060142302 - Chemical compounds: R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in...

20060142301 - Substituted 1-benzyl-4-substituted piperazine analogues: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are...

20060142303 - Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents: The present invention provides novel substituted chalcone derivatives which exhibit anti-hyperglycemic and anti-dyslipedemic activity. The invention also provides a method for treating type II diabetes and associated hyperlipidemic conditions in a mammal by administering the compounds of the present invention and compositions containing these derivatives....

20060142304 - Method for treating or preventing pruritic and neurogenic skin disorders: This invention relates to methods of treatments, compositions, and kits for providing rapid relief to the user for pruritic and neurogenic skin disorders. The invention also provides methods of treatments, compositions, and kits for preventing such conditions....

20060142305 - Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates...

20060142307 - Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions: Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of...

20060142306 - Sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers....

20060142308 - Synergistic combination comprising roflumilast and formoterol: The invention relates to the combined administration of roflumilast and formoterol for the treatment of respiratory tract disorders....

20060142309 - 8-heteroaryl xanthine adenosine a2b receptor antagonists: The present invention also relates to the preparation of the compounds, pharmaceutical formulations thereof, and their use in medicine as potent or selective A2B adenosine receptor antagonists and their uses for treating asthma, autoimmune diseases and retinal vascular diseases....

20060142310 - Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines: The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines....

20060142311 - Prodan-containing nucleotide and use thereof: wherein R3 is —OH, ═O, or —NH2, with the proviso that when R3 is —OH or —NH2, R4 is H; when R3 is ═O, R4 is —NH2; and when R3 is ═O, H is attached to the 1-position N of the purine ring, and the bond between the 1-position N...

20060142312 - C6-aryl and heteroaryl substituted pyrido[2,3-d] pyrimidin-7-ones: The present invention provides substituted 2-aminopyridines of formula I, wherein R1, A1, W, X, and Y are as defined in the specification, useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (Cdk4)....

20060142313 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease....

20060142314 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease....

20060142316 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,...

20060142315 - Substituted biaryl piperazinyl-pyridine analogues: The present invention relates to dihydrofolate reductase inhibitors having an aromatic group and a heteroaromatic group linked by a methylene group; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such dihydrofolate reductase inhibitors. More particularly, the present invention relates to dihydrofolate reductase inhibitors...

20060142317 - 3-substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof: The invention relates to 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives which are substituted in position 3 by 5-membered heteroaryl which may be fused to an aryl or heteroaryl radical, where the heteroaryl and, if appropriate, the fused aryl or heteroaryl radical may have 1, 2 or 3 substituents selected independently of one another from...

20060142318 - Compounds for treating fundic disaccomodation: wherein n is 1 or 2; p1 is 0, and p2 is 1 or 2; or p1 is 1 or 2, and p2 is 0; X is oxygen, sulfur or ═NR9; Y2 is oxygen or sulfur; R7 is hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl or phenylmethyl; R8 is C1-6alkyl, C3-6cycloalkyl phenyl or...

20060142319 - Pyridyl-substituted spiro-hydantoin crystalline forms and process: wherein Z is N or CR4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A1, A2, G, and Q are linkers; and R2, R4a, R4c, and R16 are defined in the specification. The process includes the reaction of N-substituted glycine compound and...

20060142320 - Polymorphic forms of naltrexone: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations....

20060142321 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT...

20060142322 - 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents: e

20060142323 - Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease: A family of compounds of formula (I) wherein: X is one of the following radicals: which behaves as dual site acetyl-cholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant...

20060142324 - Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands: Disclosed are compounds of formula (I) or pharmaceutically acceptable non-toxic salts or pharmaceutically acceptable solvates thereof wherein: (II) represents (a), (b), (c) or (d) and W, X, Y, A, B, C, D, E are variables as described herein. These compounds are highly selective agonists or antagonists at NK3 receptors or...

20060142325 - Fused bicyclic-substituted amines as histamine-3 receptor ligands: s

20060142330 - 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor....

20060142327 - Beta 3 adrenergic agonists: The present invention relates to a β3 adrenergic receptor agonist of formula (1) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity....

20060142328 - Beta 3 adrenergic agonists: The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity....

20060142329 - Beta 3 adrenergic agonists: The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity....

20060142326 - Use of pyrazolopyridines for the treatment of cognitive deficits: The invention relates to methods which are used to improve, increase or facilitate the cognition of individuals with neurodegenerative pathologies. More specifically, the invention relates to the use of compounds from the family of pyrazolopyridines in order to improve the cognitive faculties of individuals with neurodegenerative diseases. The invention can...

20060142331 - Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention....

20060142332 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT...

20060142333 - Vanilloid receptor modulators: e

20060142335 - Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors: The present invention relates to new substituted carbamic acid quinoline-6-yl esters of formulae 1 and 2 where R1=alkyl, aryl; R2=H, alkyl, aralkyl useful as acetylcholinesterase inhibitors, and which show potent antiacetylcholinesterase activity and have potential therapeutic use for prevention or cure of acetylcholinesterase related disorders including peripheral as well as...

20060142334 - Tetrahydroquinoline derivatives: The present invention relates to tetrahydroquinoline derivatives having gene formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are H or Me; R3 is H, hydroxy, (1-4C)alkoxy, (di)(1-4C)alkylamino(2-4C)alkoxy or (2-6)heterocycloakl(2-4C)alkoxy; R4 is H, OH, (1-4C)alkoxy or R7; R5 is H, OH, (1-4C)alkoxy or R7, with the proviso...

20060142336 - N-sulfonylpiperidines as metalloproteinase inhibitors (tace): Compounds of formula (1), wherein Z is —CONR15OH or —N(OH)CHO and X is —(CR9R10)t-Q-(CR11R12)u- (where t and u are independently 0 or 1 with the proviso that t and u cannot both be 0);are inhibitors of metalloproteinases and in particular TACE....

20060142337 - Piperidine derivative and use thereof: wherein Ar is an aryl group optionally having substituents, R is a C1-6 alkyl group, R1 is a hydrogen atom, a hydrocarbon group optionally having substituents, an acyl group or a heterocyclic group optionally having substituents, X is an oxygen atom or an imino group optionally having substituents, ring A...

20060142338 - 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060142339 - Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds....

20060142341 - Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives: a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 and R2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl; R3 is hydrogen or halo; R4 is...

20060142342 - Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives: a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 and R2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl; R3 is hydrogen or halo; R4 is...

20060142340 - Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4 antagonists: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds....

20060142343 - Pyrrolines: e

20060142344 - Method for treating hiv infection through co-administration of tipranavir and gw695634: A method for treating HIV infection through co-administration of tipranavir and GW695634....

20060142345 - 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation: 3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic...

20060142346 - S-lansoprazole compositions and methods: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is...

20060142347 - Compounds and methods for the treatment or prevention of flavivirus infections: t

20060142348 - Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease:

20060142349 - Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor: The present invention provides methods for identifying compounds useful in modulating α7 nicotinic acetylcholine receptors. The invention also provides compounds that prevent, suppress or inhibit desensitization of an α7 nicotinic acetylcholine receptor, and which resensitize such receptors. Pharmaceutical compositions, and methods of treatment, particularly in regard of neurological diseases are...

20060142350 - 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it: e

20060142351 - Method of increasing systemic tryptophan with niacin compounds: Chronic infection with retroviruses, such as HIV, induce a number of metabolic derangements. The present invention relates to a method for increasing systemic tryptophan with niacin compounds....

20060142352 - Compounds useful for the treatment of cancer, compositions thereof and methods therewith: The present invention generally relates to compounds and compositions useful for the modulation of ligase activity. The invention further relates to Compounds of the Invention, compositions thereof, and methods for treating or preventing cancer, a neoplastic disorder, acute or chronic renal failure, an inflammatory disorder, an immune disorder, a cardiovascular...

20060142353 - Cetylpyridinium salt of an anti-inflammatory agent and pharmaceutical compositions containing it: Cetylpyridinium salt of diclofenac....

20060142354 - Use of epothilone derivatives for the treatment of hyperparathyroidism: t

20060142355 - Carboxylic acid peri-substituted bicyclics for occlusive artery disease:

20060142357 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a...

20060142356 - Novel therapeutic method and compositions for topical administration: According to the invention there is provided a pharmaceutical composition suitable for topical administration to the skin which comprises farglitazar, or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier and its use in the treatment of skin conditions....

20060142358 - Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes: The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes....

20060142359 - Cyclopenta[c]isoxazole-3-amines used as protective agents for materials: e

20060142361 - Azole derivatives and methods for making the same: The present invention is broadly directed to azole derivatives that exhibit antifungal activity and methods for making the same. In one aspect, the invention includes carboxylic acid and phosphate ester derivatives of fluconazole that exhibit antifungal activity. In addition, the invention comprises methods for synthesizing the derivatives and pharmaceutical compositions...

20060142360 - Compound: wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently...

20060142362 - Heteroarylacetamide inhibitors of factor xa: e

20060142363 - Imidazolidinedione analogs useful as anticoagulants and antithrombotics:

20060142365 - Benzimidazole compounds and antiviral uses thereof: The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of...

20060142364 - Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof: Compounds of formula (I) or pharmaceutically acceptable salts thereof: Formula (I) wherein R1, R2, RF1, RF2 and Z are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060142366 - Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2: The invention relates to novel heteroaryl substituted acetone derivatives which inhibit the enzyme phospholipase A2, pharmaceutical preparations containing these compounds and a method of producing these compounds....

20060142368 - Compounds and methods for inducing apoptosis in proliferating cells: Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including...

20060142367 - Pyrazole compound: m

20060142369 - Delta 1-pyrrolines used as pesticides:

20060142370 - Sumanene and method for manufacturing the same:

20060142371 - 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor: This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the...

20060142372 - Benzofurane derivatives and the use the same as antidepressants and anxiolytics: Novel benzofuran derivatives of the formula (I) in which R1, R2, X, Y, Z and m have the meanings indicated in Patent Claim 1, they have a strong affinity to the 5-HT1A receptors. The compounds inhibit serotonin reuptake, exhibit serotonin-agonistic and -antagonistic properties and are suitable as antidepressants, anxiolytics, antipsychotics,...

20060142373 - Medicaments for the treatment or prevention of fibrotic diseases: v

20060142374 - Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same: A crystal for oral solid medicament comprised of indoline compound (KMD-3213) which exerts α1-adrenaline receptor blocking effect, is useful as a therapeutic agent for dysuria and is represented by the formula: (I) wherein in the powder X-ray diffraction pattern, the compound is characterized by main peaks of 5.5°±0.2°, 6.1°±0.2°, 9.8°±0.2°,...

20060142375 - Method for augmenting the effects of serotonin reuptake inhibitors: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer,...

20060142376 - Method for obtaining an antiepileptic agent: A process for obtaining the pharmaceutical active ingredient, levetiracetam, by means of deaminomethylation of a sufficiently pure enantiomer intermediate (S)-(II), or by means of deaminomethylation of an addition salt thereof with an acid, wherein R1 and R2 are either the same or different (C1-C6)-alkyl radicals, or else R1 and R2...

20060142378 - Amino-functionalized 1,2,4-trioxanes useful as antimalarial agents and process for preparation thereof: p

20060142377 - Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same: In only two steps and in 65% overall yield, natural trioxane artemisinin (I) was converted on gram scale into C-10-carba trioxane dimer (3). This new, very stable dimer was then transformed easily in one additional step into four different dimers (4-7). Alcohol and diol dimers (4 and 5) and ketone...

20060142379 - Use of ap-1 activators to treat glaucoma and ocular hypertension: Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed....

20060142380 - 2-phenylpyran-4-one derivatives as selective cox-2 inhibitors: The present invention relates to 2-phenylpyran-4-derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses....

20060142381 - Furancarboxamides: e

20060142382 - Skin lightening composition: A composition which comprises (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and, as occasion demands, (iii) L-ascorbic acid, a derivative thereof or a salt thereof....

20060142383 - 3d-structure model of sars coronavirus 3cl protease and anti-sars drugs: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL...

20060142384 - 2-oxyamino-1-cyclopentene-1-nitriles as material protective agents: e

20060142386 - Bis(thio-hydrazide amides) for increasing hsp70 expression:

20060142385 - Inhibitors of matrix metalloproteinase:

20060142387 - Chemical compounds: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds....

20060142388 - 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative: (wherein R1 and R2 are the same or different, and each represents a hydrogen atom, C1-10alkyl group, etc; X represents a hydrogen atom or a fluorine atom; and Y represents an amino group, —SR3, —S(O)nR7, —SCHR3R4, —S(O)nCHR3R4, —NHCHR3R4, —N(CHR3R4)(CHR5R6), —NHCOR3 or —OCOR7), a pharmaceutically acceptable salt thereof, or a hydrate...

20060142389 - Pharmaceutically useful salts of carboxylic acid derivatives: A compound selected from one or more of the following: a (1R,2S)-2-hydroxyindan-1-amine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; an L-arginine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino-2-oxoethoxyphenyl)propanoic acid; a tert-butylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino-2-oxoethoxyphenyl)propanoic acid; a choline salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; an adamantylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; a N-benzyl-2-phenylethanaminium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid; a N-benzyl-2-(benzylamino) ethanaminium salt...

20060142391 - Ppargamma-activating pharmaceutical composition: The present invention relates to PPARγ-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPARγ-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof,...

20060142390 - Treatment for severe melancholic depression: Methods for treating severe melancholic depression, comprising administering, to a subject, a preparation comprising EPA, or metabolite(s) thereof....

20060142392 - Process for preparing (2s)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives: t

20060142393 - Bis(thio-hydrazide amides) for treatment of hyperplasia:

20060142395 - Modulation of intracellular calcium signaling by n-acylethanolamines: The present invention includes compositions and methods for neuroprotection by modulating intracellular calcium concentrations by administering an effective amount of an N-acylethanolamine to a subject....

20060142394 - Use of proteases for decomposing allergens: The invention relates to the use of an active ingredient for inhibiting dust mite feces and/or mold spores as well as for denaturing the keratin of animal hair as well as plant pollen or plant spores, consisting of an enzyme such as auxillase, alcalase, bromelain, alpha-chymotrypsin, collagenase, pepsin, pronase, thrombin...

20060142396 - Use of gaba agonists for the treatment of spastic disorders, convulsions, epilepsy, and neuroprotection: A method of treating a neuronal disorder is provided that includes the intravenous administration to a subject suffering or predisposed to a neuronal disorder a therapeutically effective amount of gamma-aminobutyramide or a pharmaceutically acceptable salt thereof. Gamma-aminobutyramide has sufficient stability for intravenous administration and is able to cross the blood-brain...

20060142397 - Use of a pparalpha agonist and metormin for decreasing the serum triglycerides: The present invention relates to the combined use of a PPARα agonist and metformin for decreasing serum triglycerides....

20060142398 - Method and composition for adminstering an nmda receptor antagonist to a subject: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject....

20060135406 - Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further comprises at least...

20060135401 - Novel method of selecting immunosuppressant having little thrombocytopenic effect: The invention relates to a novel method for selecting an immunosuppressive agent with a less thrombocytopenia effect. According to the invention, a method for selecting an immunosuppressive agent which has a potent immunosuppressive activity but a lower thrombocytopenia effect, said method comprising measuring an IL-2 transcription inhibitory activity in a...

20060135402 - Oral administration of calcitonin: Disclosed is a particular method of orally administering pharmaceutical compositions comprising calcitonin in combination with oral delivery agents, prior to the consumption of food in humans, and a method of treatment of disorders responsive to the action of calcitonin employing such method of administration; also oral calcitonin pharmaceutical compositions with...

20060135405 -